Hemostemix Inc. Share Price

HEM

CA4236943060

Biotechnology & Medical Research

Market Closed - Toronto S.E. Other stock markets 15:02:37 09/07/2026 BST			5-day change	1st Jan Change
0.0600 ^CAD	0.00%		+9.09%	-33.33%

07-08	Hemostemix Files Commercialization Application for Treatment of Vascular Dementia, Refractory Angina and Pain	MT
06-26	Hemostemix Raises C$360,000 in the First Tranche of Private Placement of Share Units	MT

News in other languages: Hemostemix Inc.

10/02/25	Hemostemix : Casino auf gold
15/01/25	Hemostemix: Klininsche Studien bescheinigen bahnbrechende Stammzelltherapie
22/04/21	Hemostemix : (German Translation) Hemostemix gibt den Abschluss der Nachbeobachtung von Studienteilnehmern der klinischen Phase-II-Studie bekannt und Uplisting von HMTXF
09/04/21	Hemostemix : (German Translation – April 8, 2021)

More news

Managers and Directors: Hemostemix Inc.

Manager	Title	Age	Since
Thomas Smeenk CEO	Chief Executive Officer	-	09/02/2020
Christina Wu DFI	Director of Finance/CFO	-	04/03/2020
Fraser Henderson CTO	Chief Tech/Sci/R&D Officer	-	13/10/2021

Director	Title	Age	Since
Thomas Smeenk BRD	Director/Board Member	-	25/11/2019
Ronnie Hershmann BRD	Director/Board Member	67	08/02/2020
Loran Swanberg BRD	Director/Board Member	-	07/04/2020

More insiders

Hemostemix Inc. is an autologous stem cell therapy platform company. The Company has developed, patented, and is scaling and selling autologous (patientâ€™s own) blood-based stem cell therapies that include angiogenic cell precursors (ACP-01), later neural cell precursors (NCP-01), and cardiomyocyte cell precursors (CCP-01). It holds 91 patents on the derivation of three stem cell lineages from the patientâ€™s blood, including ACP-01, CCP-01 and NCP-01. ACP-01 is a clinically relevant and statistically significant treatment for peripheral arterial disease, chronic limb-threatening ischemia, non-ischemic dilated cardiomyopathy, ischemic cardiomyopathy, congestive heart failure, and angina. It has completed a Phase II clinical trial for chronic limb-threatening ischemia. It has two wholly owned subsidiaries, Kwalata Trading Limited and PreCerv Inc. PreCerv Inc. holds a global field of use license to ACP-01 & NCP-01 for the treatment of conditions of the central and peripheral nervous system.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
09/07/26	CA$0.0600	0.00%	28,835
08/07/26	CA$0.0600	+33.33%	81,000
07/07/26	CA$0.0450	-18.18%	29,000
06/07/26	CA$0.0550	0.00%	1,650
03/07/26	CA$0.0550	0.00%	1,000

Delayed Quote Toronto S.E.

More quotes

Income Statement and Estimates

More financial data

Market Cap	11.87M 8.39M 7.34M 6.77M 6.26M 801M 12.07M 80.92M 31.78M 394M 31.52M 30.83M 1.36B	P/E 2024	-4.36x	P/E 2025	-3.12x
Enterprise Value	14.73M 10.42M 9.11M 8.41M 7.76M 994M 14.98M 100M 39.44M 489M 39.12M 38.27M 1.68B	EV / Sales 2024	-	EV / Sales 2025	-
Free-Float	82.86%	Yield 2024 *	-	Yield 2025	-

07-08	Hemostemix Files Commercialization Application for Treatment of Vascular Dementia, Refractory Angina and Pain	MT
06-26	Hemostemix Raises C$360,000 in the First Tranche of Private Placement of Share Units	MT
06-16	Hemostemix Inc. amended terms of the transaction	CI
05-29	Hemostemix Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05-25	Hemostemix Inc. Announces the Appointment of Desire´e Cox to Board of Directors	CI
05-20	Hemostemix Inc. announced that it expects to receive CAD 1 million in funding	CI
05-01	Hemostemix Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
04-30	Hemostemix Inc. Auditor Raises 'Going Concern' Doubt	CI
03-18	Hemostemix Inc. announced that it has received CAD 0.783968 million in funding	CI
01-16	Hemostemix Receives FDA Support for Its Basket Protocol Approach	MT
12-30	Hemostemix Inc. announced that it has received CAD 0.48 million in funding	CI
12-23	Hemostemix Inc Appoints David B. Alper as Member of Scientific Advisory Board, Effective January 2026	CI
12-09	Hemostemix Inc. announced that it expects to receive CAD 0.96 million in funding	CI

07-08	Commercialization Application Filed by Hemostemix for the Treatment of Vascular Dementia, Angina and Pain	NE
06-26	Hemostemix Closes $360,000 First Tranche of Private Placement	NE
06-17	Hemostemix : rsquo; $1,000,000 Private Placement and Update	PU
06-17	Hemostemix' $1,000,000 Private Placement and Update	NE
05-26	Dr. Desiree Cox Appointed to Hemostemix Board of Directors	AQ

1 week	+9.09%
Current month	+9.09%
1 month	+9.09%
3 months	-14.29%
6 months	-29.41%
Current year	-33.33%

1 week	0.04	0.06
1 month	0.04	0.06
Current year	0.04	0.11
1 year	0.04	0.14
3 years	0.04	0.42
5 years	0.04	0.42
10 years	0	5.9

Hemostemix Inc. Share Price

Stocks

HEM

CA4236943060

Biotechnology & Medical Research

Valuation: Hemostemix Inc.

Chart: Hemostemix Inc.

Latest news : Hemostemix Inc.

Press Releases: Hemostemix Inc.

News in other languages: Hemostemix Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Hemostemix Inc.

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Income Statement and Estimates

Date	Insider	Type	Main position	Quantity	% Market Cap.
06-24	Peter Lacey	Sell	Chairman	1,000,000	0.5056%
06-24	Peter Lacey	Sell	Chairman	2,000,000	1.0111%
12-17	Loran Swanberg	Option	Director	65,000	0.0345%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
HEMOSTEMIX INC.	0.00%	+9.09%	-55.56%	-50.00%	8.39M
ARGENX SE	-4.14%	-8.06%	+57.35%	+117.24%	54.63B
WUXI APPTEC CO., LTD.	+1.84%	-0.66%	+75.79%	+93.87%	54.88B
INSMED INCORPORATED	-2.24%	+3.59%	+19.60%	+466.72%	25.06B
BIONTECH SE	-1.60%	-6.21%	-19.69%	-14.84%	23.14B
WUXI BIOLOGICS (CAYMAN) INC.	+2.43%	+1.06%	+47.70%	-0.11%	19.88B
GENMAB A/S	-3.19%	0.00%	+33.99%	-26.87%	17.55B
PHARMAESSENTIA CORPORATION	-6.84%	+2.18%	+195.12%	+357.18%	16.5B
EXELIXIS, INC.	-1.05%	+1.16%	+25.08%	+196.28%	14.2B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+8.74%	+3.51%	+53.81%	-	15.36B
Average	-0.61%	+0.66%	+43.32%	+126.61%	24.12B
Weighted average by Cap.	-0.91%	-1.46%	+55.04%	+137.78%

	2024	2025
Net sales	-	-
Net income	-2.62M -1.85M -1.62M -1.49M -1.38M -176M -2.66M -17.84M -7.01M -86.94M -6.95M -6.8M -299M	-4.71M -3.33M -2.92M -2.69M -2.48M -318M -4.79M -32.14M -12.62M -157M -12.52M -12.25M -539M
Net Debt	4.23M 2.99M 2.62M 2.41M 2.23M 285M 4.3M 28.85M 11.33M 141M 11.24M 10.99M 483M	2.86M 2.02M 1.77M 1.63M 1.51M 193M 2.91M 19.5M 7.66M 95.07M 7.6M 7.43M 327M